Thai Breast Disease Society

04/08/2026

Postmastectomy radiotherapy (PMRT) in immediate autologous breast reconstruction is generally safe and yields satisfactory aesthetic and patient-reported outcomes, though it increases specific risks like fat necrosis and overall complication rates compared to non-irradiated groups.

Explore the current issue of Plastic and Reconstructive Surgery, featuring original peer-reviewed articles, clinical studies, and the latest research.

04/08/2026

Historically, salvage mastectomy has been the default medical standard after a relapse following breast-conserving surgery (BCS) and radiotherapy. This study provides critical, large-scale clinical clarity on whether less invasive or alternative options are safe and effective.

AbstractBackground. Salvage mastectomy has long been regarded as the standard treatment for ipsilateral breast tumor recurrence (IBTR) following breast-con

04/08/2026

Coordinated care allows clinicians to safely de-escalate both axillary surgery and radiation therapy simultaneously in select low-risk older adults without worsening local control or escalating aggressive treatment paths.

Background Recent studies suggest that selective omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer may reduce morbidity without compromising oncologic outcomes. The impact of SLNB omission on eligibility for adjuvant therapies, including CDK4/6 inhibitors and partial breast....

02/08/2026

This multicenter retrospective cohort study in the Netherlands investigated care patterns and outcomes for 485 patients experiencing ipsilateral breast tumor events (IBTE) after prior breast-conserving surgery. Salvage mastectomy was performed in 89.5% of patients, while 10.5% underwent repeat breast-conserving surgery. Detailed findings from the research outline treatment choices and patient prognosis.

02/08/2026

As treatments like NST improve, surgeons are able to safely perform less extensive lymph node surgeries for occult breast cancer patients, reducing potential side effects while maintaining survival outcomes.

27/07/2026

ประชาสัมพันธ์ เพื่อขอเรียนเชิญร่วมงาน
ปฐมนิเทศ & ปัจฉิมนิเทศ แพทย์ประจำบ้านต่อยอด สาขาศัลยศาสตร์เต้านม ประจำปีการศึกษา 2569

สมาคมโรคเต้านมแห่งประเทศไทย ขอเรียนเชิญคณาจารย์ และแพทย์ประจำบ้านต่อยอด สาขาศัลยศาสตร์เต้านม ทั้งศิษย์เก่าและศิษย์ปัจจุบันทุกท่าน เข้าร่วมงาน “ปฐมนิเทศ & ปัจฉิมนิเทศ แพทย์ประจำบ้านต่อยอด สาขาศัลยศาสตร์เต้านม ประจำปีการศึกษา 2569”

กำหนดการ
📅 วันอังคารที่ 18 สิงหาคม 2569
🕡 เวลา 18.30 น. เป็นต้นไป
📍 ห้องอาหาร The Mulberry Chinese Cuisine ชั้น 10 โรงแรม The Berkeley Hotel Pratunam

21/07/2026

Precision oncology is changing the game for breast cancer treatment! HER2-positive breast cancer, historically associated with poor outcomes, has seen a dramatic shift in prognosis thanks to advancements in neoadjuvant HER2-targeted therapies.

In a newly published review in JNCCN (Journal of the National Comprehensive Cancer Network), researchers from the University of Chicago outline the current evidence guiding the optimal neoadjuvant management of early-stage HER2-positive breast cancer.

HER2-positive breast cancer accounts for approximately 15%–20% of breast cancers and was historically associated with poor outcomes. The introduction of HER2-targeted therapies has significantly improved prognosis, particularly in the treatment of early-stage disease. Neoadjuvant HER2-directed the...

21/07/2026

As reported in The Lancet Oncology by Kaidar-Person et al, an unplanned subset analysis at 20 years in the phase III EORTC trial 22922/10925 showed that internal mammary and medial supraclavicular (IM-MS) nodal irradiation was associated with a significantly lower rate of breast cancer mortality—but no benefit in non–breast cancer mortality—compared with no IM-MS in patients with node-negative stage I to III breast cancer.

21/07/2026

In cN1 breast cancer, an imaging-defined burden of ≥4 suspicious nodes behaves pathologically much like cN2a disease.

Future Staging: Subcategorizing clinical N1 disease based on node count rather than just mobility could significantly improve future staging frameworks, surgical planning, and eligibility criteria for clinical trials.

Background The current American Joint Committee on Cancer (AJCC) staging system defines cN1 by node mobility rather than number, while pathologic staging stratifies by node count. Whether cN1 patients with four or more suspicious nodes on pretreatment imaging differ in pathologic stage and survival....

21/07/2026

Modern HRD-directed treatment with chemotherapy plus olaparib matches the efficacy of intensified chemotherapy while offering a significantly more favorable safety profile.